Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today reported a substantial reduction in tumor burden from a single-patient expanded access case in ...

Penn Medicine researchers found two oral drugs eliminated dormant breast cancer cells in most patients, with relapse rates ...

A drug that costs 5p per tablet and is already widely used to treat malaria may also cut the chances of breast cancer ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Celcuity Inc. is one of them.

Kazia Therapeutics ( ($KZIA) ) just unveiled an update. On October 2, 2025, Kazia Therapeutics announced an 86% reduction in tumor burden in a ...

The emergence of drug resistance remains one of the greatest challenges in effective cancer therapy. Despite advances in ...

Animal studies say rapamycin can slow aging – but does it work in humans? A new review finds the evidence for the off-label, ...

Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company developing innovative therapies for ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...

Primary liver cancer is the third leading cause of cancer-related deaths, of which hepatocellular carcinoma (HCC) accounts for approximately 90% of all liver cancer cases. Given that the development ...

Kazia Therapeutics (KZIA) reported a substantial reduction in tumor burden from a single-patient expanded access case in triple-negative breast ...

A large cohort study adds evidence that nicotinamide can prevent skin cancer in patients with previous skin cancers and solid ...